Earnings Releases·Nov 4, 2026, 4:08 PM ET

Veracyte — Third Quarter 2026 Earnings Summary

Total revenue grew 15% year-over-year to $151.8 million, driven by 15% growth in testing revenue and a 40% increase in product revenue to $4.6 million; GAAP net income rose to $31.5 million ($0.38 per share), while non-GAAP diluted EPS remained flat at $0.51.
Full-year 2026 revenue guidance was revised downward to $590–$593 million (14–15% growth) and testing revenue guidance lowered to $571–$573 million (16% growth), with adjusted EBITDA margin expected to exceed 26%.
The Board authorized a new $100 million share repurchase program expiring in 12 months, and the company acquired Convergent Genomics to expand its urinary tumor DNA testing platform for bladder cancer.
Strategic milestones included securing Medicare reimbursement for the Prosigna Breast ROR test, strong adoption of Prosigna IVD following OPTIMA trial results, and surpassing 1 million patients served, despite Decipher Prostate volume falling below expectations.